

- 55) The composition according to claim 49, wherein said buffer is a citrate-phosphate buffer.
 - 56) The composition according to claim 48, further comprising a bactericidal or bacteriostatic agent as a preservative.
-
- 57) The composition according to claim 48, wherein said lytic enzyme is lyophilized.
 - 58) The composition according to claim 48, wherein said at least one lytic enzyme is present in a concentration of about 100 to about 100,000 active enzyme units per milliliter of fluid in the wet environment of the nasal or oral passages.
 - 59) The composition according to claim 48, wherein said at least one lytic enzyme is present in a concentration of about 100 to about 10,000 active enzyme units per milliliter of fluid in the wet environment of the nasal or oral passages.


IN THE ABSTRACT

Please cancel the abstract and replace with the following:

– A lozenge for the treatment of *Streptococcus Group A* infections of the mouth, throat, and nasal passage is disclosed which comprises a lytic enzyme composition specific for *Streptococcus Group A* and a lozenge carrier for delivering the lytic enzyme.-

The application is now in condition for allowance. Please call the undersigned at (301) 603-9071 if you have any questions or comments. Thank you.

Very truly yours,



John S. Johnson

12